The ASX VGS makes it easy to invest in several global investment megatrends via a single trade. The post 3 megatrends ...

Australia's S&P/ASX 200 slipped 0.3% to 8,160.00 ... which sank 6.3% amid concerns about two of the drugmaker’s blockbuster products: diabetes treatment Mounjaro and weight loss counterpart Zepbound.

Australia’s S&P/ASX 200 slipped 0.3% to ... about two of the drug maker’s blockbuster products: diabetes treatment Mounjaro and weight loss counterpart Zepbound. Also falling was Trump Media ...

Drugmaker Eli Lilly‘s stock tumbled by 6% after the company missed profit and revenue expectations for Q3 primarily due to ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Sales of Zepbound and Mounjaro, the name under which the same drug is sold to treat Type 2 diabetes, both fell well short of Wall Street estimates.

During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro ...

But those wholesalers tapped into some of that existing stock in the third quarter instead of buying more from the company, which dampened revenue from both treatments, Eli Lilly said. Mounjaro ...

Mounjaro and Zepbound’s big sales miss disappointed investors, causing the stock to plummet. Lilly’s stock has risen 55.0% so far this year compared with an increase of 17.6% for the industry.